Dr. Pedro de Marchi, ONCOCLINICAS, Brazil
Dr. Pedro de Marchi is a leading medical oncologist specializing in head and neck cancer at Oncoclínicas, Brazil. He serves as the National Leader and Medical Coordinator, alongside being a Professor of Medicine at Universidade Estadual do Rio de Janeiro. Dr. Marchi completed his MD at Universidade Federal de Santa Maria and furthered his training in internal medicine and oncology. His research focuses on the efficacy of immune checkpoint inhibitors and head and neck squamous cell carcinoma. Dr. Marchi has led several significant studies and has been involved in numerous conferences to advance cancer treatment. 🎗️👨⚕️📚
Publication Profile
Google Scholar
Education
Dr. Pedro de Marchi earned his MD from Universidade Federal de Santa Maria (UFSM) in 2008. He completed a residency in Internal Medicine at the Universidade Federal do Rio Grande do Sul and a Clinical Fellowship in Medical Oncology at Hospital São Lucas (PUC-RS). He further enriched his expertise through an observership at The University of Texas MD Anderson Cancer Center. Dr. Marchi holds a Master’s in Oncology from Fundação Pio XII, focusing on chemotherapy toxicity in head and neck cancer, and a PhD in Oncology, studying immune checkpoint inhibitors and biomarkers in lung cancer. 🎓💉📖
Experience and Service
Dr. Pedro de Marchi has an extensive career in oncology, serving as a resident at Universidade Federal do Rio Grande do Sul (2009-2011) and a Medical Oncology Fellow at Hospital São Lucas (2011-2014). He was the Head of Thoracic and Head & Neck Oncology at Barretos Cancer Hospital (2016-2020) and is currently a National Leader in Head & Neck Cancer at Oncoclínicas. In addition, he coordinates multiple fellowship programs and serves as a Professor of Medicine at Universidade Estadual do Rio de Janeiro. His leadership roles reflect his commitment to advancing oncology care and research. 🩺🌟📚
Honors and Awards
Dr. Pedro de Marchi was recognized with the AMRIGS Medical Qualification by the Medical Association of Rio Grande do Sul in Porto Alegre, Brazil, in 2008. This prestigious honor highlights his dedication to the medical field and his commitment to achieving excellence in healthcare. The award underscores his professional qualifications and serves as a testament to his skills as a medical practitioner. Dr. de Marchi’s achievements reflect his continuous pursuit of knowledge and his contribution to advancing medical practice in Brazil. 🏆🎓🌟
Research Contributions
Dr. Pedro de Marchi has made significant contributions to cancer research through various grants and contracts. As the Principal Investigator, he led studies on head and neck squamous cell carcinoma epidemiology and COVID-19 mortality determinants among cancer patients, securing substantial funding from notable organizations like MSD, AMGEN, and AstraZeneca. His research includes pivotal Phase III trials assessing innovative treatments for squamous cell carcinoma. These efforts not only advance medical knowledge but also aim to improve patient outcomes in Brazil. Dr. de Marchi’s work is essential in addressing critical health challenges in oncology. 📊🔬🎗️
Teaching
Dr. Pedro de Marchi plays a vital role in medical education and mentorship. He serves as a Clinical Research Mentor in the Oncoclinicas Mentorship Programme since 2024, fostering the next generation of oncologists. As a Professor at Universidade Estadual do Rio de Janeiro (UERJ), he instructs rotating medical students, enhancing their clinical skills. Additionally, Dr. de Marchi supervises postdoctoral research fellows in Internal Medicine and Thoracic and Head & Neck Medical Oncology, guiding them in their academic and clinical pursuits. His commitment to education ensures that future physicians are well-equipped for the challenges of oncology. 📚👨⚕️🎓
Conclusion
Dr. Pedro de Marchi exemplifies the qualities sought after for the Research for Academic Engagement Excellence Award. His leadership in cancer research, dedication to education, and significant contributions to the field make him a suitable candidate for this prestigious recognition.
Publication Top Notes
- Pembrolizumab versus chemotherapy for untreated PD-L1-expressing NSCLC (KEYNOTE-042) 🌟 — Cited by: 3065, Year: 2019
- Durvalumab plus platinum–etoposide for extensive-stage SCLC (CASPIAN) 🎯 — Cited by: 1679, Year: 2019
- First-line nivolumab plus ipilimumab and chemotherapy in NSCLC (CheckMate 9LA) 🚀 — Cited by: 1086, Year: 2021
- Durvalumab with/without tremelimumab for extensive-stage SCLC (CASPIAN) ⚖️ — Cited by: 487, Year: 2021
- CheckMate 9LA 2-year update: nivolumab plus ipilimumab and chemotherapy vs. chemotherapy alone 🕒 — Cited by: 172, Year: 2021
- Lung cancer in Brazil 🇧🇷 — Cited by: 142, Year: 2018
- PD-L1 expression in NSCLC: TPS vs. CPS 🧬 — Cited by: 77, Year: 2021
- Câncer de pulmão no Brasil 📈 — Cited by: 70, Year: 2018
- MiR-21 as a prognostic biomarker in head and neck SCC 📊 — Cited by: 69, Year: 2017
- Determinants of COVID-19 mortality in cancer patients in Brazil 🦠 — Cited by: 50, Year: 2021